Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Pongwut Danchaivijitr et al.|New England Journal of Medicine|2024Cited by 369
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerCaicun Zhou, Pasi A. Jänne, Suresh S. Ramalingam et al.|JAMA Oncology|2021Cited by 289
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Nobumasa Mizuno et al.|Journal of Clinical Oncology|2023Cited by 100
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81